Xcout Intel
Xintela AB
Xintela AB is a Swedish biotechnology company developing cell therapies and regenerative-medicine products based on its integrin α10 technology. Its lead program, XSTEM, uses integrin α10-selected mesenchymal stem cells for conditions such as osteoarthritis and cartilage damage, serving patients and healthcare providers through potential advanced therapies.
Subscribe to see Xintela AB’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Xintela AB competitors
A few of Xintela AB's closest competitors — see the full list of competitors and alternatives →
Tavra Biosciences supplies cGMP-manufactured stem cell biologics, specifically bone marrow-derived mesenchymal stem cells, to licensed physicians for localized clinical use in orthopedic and regenerative medicine. The company's off-the-shelf products are manufactured in a compliant cleanroom facility and provided to support clinical practices in sports medicine and pain management.
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
CO.DON is a biopharmaceutical company specializing in tissue engineering and the development and manufacturing of personalized cell therapies. The company provides regenerative treatments for joint cartilage defects to medical professionals and patients.
Cynata Therapeutics is a biotechnology research company headquartered in Cremorne, Australia, focused on therapeutic products and stem cell technology.
UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE, is presently undergoing Phase 2 clinical trials, targeting both osteoarthritis and chronic kidney disease. Beyond therapeutics, the company also offers UnicoVial, a specialized cryopreservation and drug containment system designed for cell therapy products, and provides a range of related testing services.
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Get Xintela AB's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Xintela AB in Xcout Intel
- The full competitor set, tracking, exports and API access